

REGISTRATION

19th Annual International Lung Cancer Congress®

First Name

Middle Initial

Last Name

Degree(s)

☐ Physician

☐ Fellow

☐ PA-C

☐ Nurse

☐ NP

☐ Pharmacist

☐ Other

Are you employed by a for-profit organization, including biotech, financial, and pharmaceutical, defined as "Industry" by PER®?

☐ Yes

☐ No

Address type:

☐ Home

☐ Hospital

☐ Office

Mailing Address

City

Prov/State

Country

Postal/Zip Code

E-mail (Your confirmation will be sent via e-mail)

Phone type:

☐ Home

☐ Mobile

☐ Work

Phone

Fax

Specialty

Birth Date (MM/DD/YYYY)

Institute /Organization

Practice Setting:

☐ Academic medical center/university

☐ Laboratory/basic research

☐ Pharmacy

☐ Community hospital-based practice

☐ Government agency

☐ Community office-based practice

☐ Pharmaceutical/biotechnology company

☐ In training (fellow, resident, student)

☐ Other

What is your principal activity?

☐ Patient care

☐ Clinical research

☐ Teaching/training

☐ Administrative

☐ Other

Preferred educational formats:

☐ Live

☐ Online

☐ Print

Preferred methods of communication:

☐ Phone

☐ Mail

☐ E-mail

Would you like to participate in CME surveys?

☐ Yes

☐ No

How many cancer patients do you treat each month?

Years practicing medicine

Would you like to enroll in the PER Point System?

☐ Yes

☐ No

Registration fees include continental breakfasts, breaks, receptions and e-syllabus materials.

All payments must be made by a draft on a United States bank.

Physicians' Education Resource®, LLC (PER®) fully complies with the legal requirements of the ADA and the rules and regulations thereof. If any participant in this educational activity is in need of accommodations, please notify us in order to receive service. Please call (609) 378-3701.

Physicians' Education Resource®, LLC reserves the exclusive rights to all recordings or reproductions of the conference and supporting materials. Unauthorized recording, by any means, is expressly prohibited. This includes, but is not limited to, recording of presentations or reproductions of supporting audio/visual materials, exhibits, and other supporting Continuing Education materials. By attending a PER® conference, meeting or related activity ("Events"), all participants, attendees, exhibitors, sponsors, and guests ("you") create an agreement between you and PER® regarding the use and distribution of your image, including but not limited to your name, voice, and likeness ("Image"). By attending the Events, you acknowledge and agree that photographs, video, and/or audio recordings may be taken of you and you grant permission to PER® (and its agents) to utilize, in perpetuity, your Image in any electronic or print distribution, or by other means hereinafter created, both now and in the future, for any lawful purpose as determined by PER®.

PER® complies with the Physician Payments Sunshine Act as part of the Affordable Care Act. Accordingly, we may be required to collect information on transfers of value provided to any covered recipient under the Act.

Signature



Physicians' Education Resource®, LLC
2 Clarke Drive, Suite 110
Cranbury, NJ 08512

19th Annual
International
Lung Cancer
CONGRESS®

JULY 26-28, 2018
Hyatt Regency Huntington Beach
21500 Pacific Coast Highway
Huntington Beach, CA 92648

Physicians' Education Resource®, LLC would like to acknowledge the following for their support:



Visit us at

gotoper.com/go/ILC18TRI

Join us for this 3-day dynamic and engaging activity!

19th Annual
International
Lung Cancer
CONGRESS®

JULY 26-28, 2018
Hyatt Regency Huntington Beach
21500 Pacific Coast Highway
Huntington Beach, CA 92648

Meet the Co-Chairs!



David R. Gandara, MD
Professor of Medicine
Division of Hematology/Oncology
Director, Thoracic Oncology Program
Senior Advisor to the Director
UC Davis Comprehensive Cancer Center
Sacramento, CA



Roy S. Herbst, MD, PhD
Ensign Professor of Medicine
(Medical Oncology)
Professor of Pharmacology
Chief of Medical Oncology
Associate Director for Translational Research
Yale Cancer Center
Yale School of Medicine
New Haven, CT

Earn a maximum of
21.75 AMA PRA
Category 1
Credits™.

To register visit
gotoper.com/go/ILC18TRI



Faculty

Paul Baas, MD, PhD
The Netherlands Cancer Institute
Amsterdam, The Netherlands

Lyudmila A. Bazhenova, MD
University of California, San Diego
San Diego, CA

Paul Bunn, Jr., MD
Division of Medical Oncology
Aurora, CO

David P. Carbone, MD, PhD
The Ohio State University Comprehensive
Cancer Center
Columbus, OH

Anne Chiang, MD, PhD
Smilow Cancer Network
New Haven, CT

Hak Choy, MD
UT Southwestern Medical Center
Dallas, TX

Max Diehn, MD, PhD
Stanford University School of Medicine
Stanford, CA

Roy H. Decker, MD, PhD
Yale University School of Medicine
New Haven, CT

Sarah B. Goldberg, MD, MPH
Yale Cancer Center
New Haven, CT

David Harold Harpole Jr., MD
Duke University School of Medicine
Durham, NC

Laurence J Heifetz, MD, FACP
Medical Director, Gene Upshaw Memorial Tahoe
Forest Cancer Center
Truckee, CA

Fred R. Hirsch, MD, PhD
University of Colorado Cancer Center
Aurora, CO

Karen Kelly, MD
UC Davis Comprehensive Cancer Center
Sacramento, CA

Corey J. Langer, MD, FACP
University of Pennsylvania
Philadelphia, PA

Primo Lara, Jr., MD
UC Davis Comprehensive Cancer Center
Truckee, CA

Benjamin P. Levy, MD
Mount Sinai Hospital
New York, NY

Gilberto de Lima Lopes Junior, MD, MBA, FAMS
Sylvester Comprehensive Cancer Center at the
University of Miami and the Miller School of
Medicine
Miami, FL

Philip C. Mack, PhD
UC Davis Comprehensive Cancer Center
Sacramento, CA

Tetsuya Mitsudomi, MD
Kindai University Faculty of Medicine
Ohno-Higashi, Osaka-Sayama, Japan

Tony Mok, MD
Chinese University of Hong Kong
Hong Kong, China

Sai-Hong Ignatius Ou, Md, PhD
University of California Irvine Healthcare
Orange, CA

Vassiliki Papadimitrakopoulou, MD
MD Anderson Cancer Center
Houston, TX

Harvey I. Pass, MD
NYU Langone Medical Center
New York, NY

Karen L. Reckamp, MD
City of Hope Comprehensive Cancer Center
Duarte, CA

Jonathan Riess, MD, MS
UC Davis Comprehensive Cancer Center
Sacramento, CA

Giorgio Scagliotti, MD, PhD
University of Torino
Orbassano (Torino), Italy

Frances A. Shepherd, MD, FRCPC, OOnt, OC
Professor of Medicine, University of Toronto
Toronto, Canada

Everett E. Vokes, MD
University of Chicago Medicine and
Biological Sciences
Chicago, IL

Heather A. Wakelee, MD
Member, Stanford Cancer Institute
Stanford, CA

Ignacio I. Wistuba, MD
The University of Texas MD Anderson
Cancer Center
Houston, TX

*Faculty accurate at time of printing

Agenda

Thursday, July 26		
6:15 AM	Registration and Breakfast	
7:15 AM	Welcome, Introductions, and Pre-session Survey	
Diagnostics and Staging		Chair: TBA
7:30 AM	New Strategies for Early Detection of Lung Cancer	Maximilian Diehn, MD, PhD
7:50 AM	Interventional Pulmonology: Using Endobronchial and Other Techniques to Optimize Diagnosis and Therapy in Lung Cancer	TBA
Early-Stage Thoracic Malignancies		Chair: Harvey I. Pass, MD
8:10 AM	Current Status of Adjuvant Therapy for NSCLC	Paul Bunn, Jr., MD
8:30 AM	Current Surgical Approaches for Early-Stage NSCLC	Harvey I. Pass, MD
8:50 AM	Applications of Radiation Therapy in Early-Stage NSCLC	Roy Decker, MD, PhD
9:10 AM	Approach to Preoperative Window-of-Opportunity Studies of Novel Therapeutics (including Immunotherapy)	Karen Kelly, MD
9:30 AM	Case-Based Panel Discussion: Staging and Management of Early-Stage NSCLC	Moderator: Harvey I. Pass, MD
9:50 AM	Break	
Translational Research in Lung Cancer: Improving Medicine Through Science		Chair: Roy S. Herbst, MD, PhD
10:15 AM	Keynote: Changing Therapeutic Landscape in NSCLC: Future Prospects	Tony Mok, MD
10:35 AM	Worldwide Landscape of Master Protocols in Lung Cancer	Vassiliki Papadimitrakopoulou, MD
10:55 AM	Rapid Translation of Bench-to-Bedside Concepts	David P. Carbone, MD, PhD
11:15 AM	Post-session Survey	
Workshop 1: Molecular Tumor Board		Chair: Sarah B. Goldberg, MD, MPH
11:20 AM	Molecular Tumor Board	TBA
12:10 PM	Poster Discussion	Jonathan Riess, MD, MS
12:30 PM	Break for Lunch	
Workshop 2: The Next Generation of Targeted Agents for Lung Cancer		Chair: David R. Gandara, MD
1:45 PM	Pre-session Survey	
1:55 PM	Keynote: The Next Generation of Agents for Lung Cancer: Overview	TBA
2:10 PM	MET-targeted Strategies	Karen L. Reckamp, MD
2:25 PM	Strategies for Overcoming KRAS Mutations	Roy S. Herbst, MD, PhD
2:40 PM	Targeting ROS1 and TRK Rearrangements	TBA
2:55 PM	Accumulating Data on RET Fusions in Lung Cancer	Paul Baas, MD, PhD
3:10 PM	Break	
3:35 PM	New Agents in Small-cell Lung Cancer	Frances A. Shepherd, MD, FRCPC
3:50 PM	Managing Patients With BRAF-mutant NSCLC	Giorgio Scagliotti, MD, PhD
4:05 PM	PARP Inhibitors: New Insights	Jonathan Riess, MD, MS
4:20 PM	Update on Targeting the HER Family in NSCLC	David R. Gandara, MD
4:35 PM	New Antiangiogenic Agents (including mABs and TKIs)	Primo N. Lara, Jr., MD
4:50 PM	Post-session Survey	
5:00 PM	Adjourn for the Day	
6:00 PM - 7:00 PM Welcome Reception in the Exhibit Hall		
Friday, July 27		
6:15 AM	Registration and Breakfast	
7:15 AM	Welcome, Introductions, and Pre-session Survey	
Combined Modality Therapy for NSCLC		Chair: Everett E. Vokes, MD
7:30 AM	Multidisciplinary Standards of Care in 2018 for Patients With Stage III NSCLC	Everett E. Vokes, MD
7:50 AM	Surgical Approaches for Locally Advanced NSCLC	David H. Harpole Jr., MD
8:10 AM	Introduction of Novel Therapeutics to Chemoradiation Therapy: Paradigms for Stage III NSCLC	Corey J. Langer, MD, FACP
8:30 AM	Controversies in Radiation Therapy for Locally Advanced Lung Cancer (NSCLC and SCLC)	Roy Decker, MD, PhD
8:50 AM	Case-Based Panel Discussion: Combined Modality Therapy	Moderator: Everett E. Vokes, MD
Eleventh Annual Addario Foundation Keynote Lecture		
9:10 AM	Introduction and Award	David R. Gandara, MD, and Roy S. Herbst, MD, PhD
9:15 AM	TBA	
9:45 AM	Break	
Immunotherapy in NSCLC (Part I)		Chair: TBA
10:10 AM	Keynote: Overview of Immunotherapy in Lung Cancer in 2018	Anne Chiang, MD, PhD
10:30 AM	Combining Immunotherapy With Chemotherapy	Corey J. Langer, MD, FACP
10:50 AM	Combining Immunotherapy With Targeted Agents	Sarah B. Goldberg, MD, MPH

Lectures Include a 5-minute Question & Answer Session

Medical Crossfire®: Will Future Biomarker Testing for Immunotherapy Be Based on PD-L1 or TMB?		
11:10 AM	PD-L1	Fred R. Hirsch, MD, PhD
11:25 AM	TMB	David P. Carbone, MD, PhD
11:45 AM	Postsession Survey	
11:50 AM	Medical Crossfire®: Current Controversies in Immunotherapy in Lung Cancer	TBA
12:30 PM	Break for Lunch	
State-of-the-Art Treatment of Advanced NSCLC		Chair: Heather Wakelee, MD
1:45 PM	Precession Survey	
1:50 PM	TBA	TBA
2:10 PM	Sequencing EGFR TKI Therapy in 2018	Tetsuya Mitsudomi, MD, PhD
2:30 PM	First- and Next-Generation ALK Inhibitors	TBA
2:50 PM	Strategies for Management of Oligometastatic Disease	Roy Decker, MD, PhD
3:10 PM	Medical Crossfire®: Frontline Therapy for Oncogene-Driven NSCLC: First- vs Third-Generation Agents	Moderator: Heather Wakelee, MD
3:40 PM	Break	
Challenges and Opportunities in Lung Cancer and Mesothelioma		Chair: TBA
4:05 PM	New Directions and Strategies for Maintenance Therapy	Heather Wakelee, MD
4:25 PM	Strategies to Address Unmet Needs in Small Cell Lung Cancer	Primo N. Lara, Jr., MD
4:45 PM	New Directions in the Therapy of Mesothelioma	Paul Baas, MD, PhD
5:05 PM	Postsession Survey	
5:10 PM	Case-Based Panel Discussion: State-of-the-Art Challenges and Opportunities in Lung Cancer	Moderator: Gilberto de Lima Lopes Junior, MD, MBA, FAMS
05:30 PM	Adjourn for the Day	
6:00 PM - 7:00 PM Get Acquainted Reception in the Exhibit Hall		
Saturday, July 28		
6:15 AM	Registration and Breakfast	
7:15 AM	Welcome, Introductions, and Precession Survey	
Immunotherapy in NSCLC (Part II)		Chair: TBA
7:25 AM	Combination Immunotherapies: What's Hot and What's Not	Karen L. Reckamp, MD, and Roy S. Herbst, MD, PhD
7:45 AM	New Classes of Immunotherapies: Beyond PD-1/PD-L1	Lyudmila A. Bazhenova, MD
8:05 AM	Immunotherapy and Combinations in Small Cell Lung Cancer	Paul Bunn, Jr., MD
8:25 AM	TBA	TBA
8:45 AM	Pseudoprogressive and Hyperprogressive Disease on Immunotherapy	Giorgio Scagliotti, MD, PhD
9:05 AM	Managing Unique Adverse Events With Immunotherapy	TBA
9:25 AM	Comparative Economics of Immunotherapy	Gilberto de Lima Lopes Junior, MD, MBA, FAMS
9:40 AM	Postsession Survey	
9:50 AM	Break	
Workshop 3: Multidisciplinary Tumor Board		Chair: Primo N. Lara, Jr., MD
10:15 AM	Interactive Case-Based Tumor Board	TBA
Personalized Therapy for NSCLC		Chair: TBA
11:15 AM	Precession Survey	
11:25 AM	Evolution of Personalized Therapy Strategies: Status in 2018	Karen Kelly, MD
11:45 AM	Revised Guidelines for Molecular Testing in NSCLC	Fred R. Hirsch, MD, PhD
12:05 PM	Break for Lunch	
01:25 PM	Liquid Biopsies and Biomarkers in the Genomic Era	Philip C. Mack, PhD
01:45 PM	Recent Advances in Diagnostic Molecular Pathology of Lung Cancer	Ignacio I. Wistuba, MD
02:05 PM	Personalized Therapy: Second-Line and Beyond	Frances A. Shepherd, MD, FRCPC, OOnt, OC
02:25 PM	Addressing Disparities in Care for Special Populations in Lung Cancer (including Women, Elderly Patients, Performance Status 2)	Laurence J. Heifetz, MD, FACP
02:45 PM	Overcoming Mechanisms of Acquired Resistance in Oncogene-Driven Lung Cancer	Sarah B. Goldberg, MD, MPH
03:00 PM	Postsession Survey	
03:10 PM	Interactive Panel Discussion: Future Perspectives on Lung Cancer Therapy	TBA
03:30 PM	Closing Remarks and Adjourn	

*Agenda accurate at time of printing

Lectures Include a 5-minute Question & Answer Session

Physicians’ Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC designates this live activity for a maximum of 21.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians’ Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669 for 21.75 Contact Hours.

This activity is supported by educational grants from Bristol-Myers Squibb and Lilly.

For further information concerning Lilly grant funding visit www.lillygrantoffice.com.